Two digital health companies focused on sleep published data this week that highlighted the efficacy of their respective platforms, bringing continued attention to the space after a CES week where ...
ResMed, a medical device company focused on sleep apnea, has launched its first consumer product, a $149 device for tracking and improving sleep called S+. The platform includes a non-contact, ...
Expands ResMed’s sleep management software solution, will help sleep labs and physicians more efficiently guide patients into and through diagnosis to long-term treatment Diagnostic management ...
ResMed, a leader in digital health with over 22.5 million cloud-connected devices sold, excels in treating respiratory disorders like sleep apnea, impacting over 1 billion globally. Recent data from ...
ResMed Inc . (NYSE:RMD; ASX:RMD), a leading player in the sleep and respiratory care market, has demonstrated strong operational performance in recent quarters. However, the company faces potential ...
SYDNEY--(BUSINESS WIRE)--ResMed today announced it has teamed up with Rugby League Hall of Fame inductee, current NSW Blues State of Origin head coach, and Channel 9 commentator Brad Fittler to help ...
SAN DIEGO, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD), the leading health technology company focused on sleep, breathing, and care delivered in the home, today announced the ...
ResMed shares are selling on the expensive side of a fair value but the numbers and growth potential make us bullish on the stock. Fundamentals are strong and the forecast 6.3% annual market growth ...
SAN DIEGO, Feb. 12, 2024 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) launched today its AirCurve 11 series devices, the company’s newest bilevel devices that use two levels of support, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback